Publication
Title
Economic evaluations applied to hepatitis B vaccination: general observations
Author
Abstract
Since HE vaccines became available, there have been many economic evaluations on HE vaccination programs. The majority of them were for countries of low endemicity. Economic evaluations for countries of very low endemicity with a good surveillance system in place and high attendance of Sexually Transmitted Disease- and IntraVenous Drug Users-clinics indicate that risk group vaccination is the most cost-effective strategy to control HB. In analyses for low endemic countries, recommendations have shifted from risk group vaccination In the eighties to universal vaccination or either infants or adolescents in the nineties. For the health care payer, the resulting cost-effectiveness ratios of universal vaccination were Favourable in comparison to those of other preventive interventions. From a societal point of view, universal HE vaccination was found to be cost-saving in these countries. Few published studies were set in countries of intermediate to high endemicity. They indicate that for the health care payer universal HE vaccination of neonates or infants is cost-effective compared to other interventions, or even cost-saving. Further studies are needed to support decision making in high endemic countries, where both the need for HE vaccination and the pressure on resources are highest. (C) 1998 Elsevier Science Ltd. All rights reserved.
Language
English
Source (journal)
Vaccine / International Society for Vaccines. - Amsterdam
Publication
Amsterdam : 1998
ISSN
0264-410X
Volume/pages
6:S(1998), p. 84-92
ISI
000077892000024
Full text (Publishers DOI)
Full text (publishers version - intranet only)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 08.10.2008
Last edited 06.03.2017
To cite this reference